Director, Oncology Clinical Pharmacology
Pfizer, Inc.
Dr. Mohamed Elmeliegy holds a position as a Director, Oncology Clinical Pharmacology department at Pfizer. Prior to joining Pfizer, he held several positions in Novartis. Dr. Elmeliegy leads a team that provides clinical pharmacology and pharmacometrics input for different phases of development for CD3 bispecifics, small molecules, monoclonal antibodies, biosimilars, and follow-on biologics. He's an Affiliate Faculty in the University at Buffalo SUNY, Buffalo, New York and the University of California San Diego. He received his PhD from St. Jude Children Research Hospital and the University of Tennessee (Memphis, TN) and completed a post-doctoral fellowship with Dr. Wojciech Krzyzanski and Dr. William J. Jusko at the Department of Pharmaceutical Sciences at SUNY Buffalo. He chaired the clinical pharmacology programming at AAPS Scientific Programming Committee for 2 years and is serving as the vice chair for the Life Cycle Management community and on the Steering Committee for the Biologics community in ASCPT. He’s member of several working streams of the IQ consortium.
Disclosure(s): Pfizer, Inc.: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Meet the Expert in the Real-World: Real-World Data in Drug Development and Utilization - Part 1
Thursday, March 28, 2024
9:30 AM – 10:30 AM MDT
Meet the Expert in the Real-World: Real-World Data in Drug Development and Utilization - Part 2
Thursday, March 28, 2024
1:30 PM – 2:30 PM MDT